New state-of-the-art facility to develop immunotherapy assets to address unmet needs in cancer treatment

SINGAPORE - Media OutReach - 28 June 2023 – Biosyngen, an immuno-oncology company with technology targeting the unmet medical needs in solid tumour and lymphoma treatment, today announced the official opening of its latest Good Manufacturing Practice (GMP) facility in Singapore.

Read more: Immuno-oncology company Biosyngen opens new cell therapy GMP facility in Singapore